Cartesian Therapeutics (RNAC) Equity Average (2016 - 2025)
Cartesian Therapeutics (RNAC) has disclosed Equity Average for 10 consecutive years, with -$81.0 million as the latest value for Q4 2025.
- On a quarterly basis, Equity Average fell 2579.07% to -$81.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$81.0 million, a 2579.07% decrease, with the full-year FY2025 number at -$66.5 million, up 70.24% from a year prior.
- Equity Average was -$81.0 million for Q4 2025 at Cartesian Therapeutics, down from -$19.2 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $89.4 million in Q4 2022 to a low of -$278.5 million in Q1 2024.
- A 5-year average of -$14.6 million and a median of -$11.7 million in 2021 define the central range for Equity Average.
- Peak YoY movement for Equity Average: tumbled 10166.94% in 2021, then surged 4615.96% in 2022.
- Cartesian Therapeutics' Equity Average stood at $1.9 million in 2021, then soared by 4615.96% to $89.4 million in 2022, then tumbled by 312.52% to -$189.9 million in 2023, then skyrocketed by 98.41% to -$3.0 million in 2024, then tumbled by 2579.07% to -$81.0 million in 2025.
- Per Business Quant, the three most recent readings for RNAC's Equity Average are -$81.0 million (Q4 2025), -$19.2 million (Q3 2025), and -$12.2 million (Q2 2025).